Berberine (Isoquinoline Alkaloid · Blood Glucose · Lipid Metabolism)
| Compound | Berberine |
| Chemical class | Alkaloid — Isoquinoline (Protoberberine) |
| CAS | 2086-83-1 |
| Primary source | Berberis aristata (tree turmeric), Hydrastis canadensis (goldenseal), Coptis chinensis (Huang Lian) |
| Key applications | Blood glucose, lipid metabolism, gut microbiome, cardiovascular |
| Claim strength | High |
| Typical form | Berberine HCl 95% or 98%; Berberis extract 10%; Goldenseal extract |
| Buy from Herbuno | Goldenseal Extract Powder → |
Commercial source: Berberine is commercially available as a high-purity hydrochloride salt (95–98% HPLC) from Berberis aristata and Coptis chinensis sources, and as a standardised 10% Berberis extract powder. See sourcing options below. Traditional use: Berberine-containing plants have been used across multiple traditional systems: goldenseal (Hydrastis canadensis) in Native American and Western herbal medicine for infections and digestive complaints; Indian barberry (Berberis aristata, Daruhaldi) in Ayurveda for liver conditions, diabetes, and antimicrobial applications; Huang Lian (Coptis chinensis) in TCM as one of the most important anti-inflammatory and anti-infective herbs, used for over 3,000 years. Research trajectory: Berberine has one of the strongest human clinical evidence bases of any botanical alkaloid, with multiple large RCTs demonstrating glycaemic control, lipid reduction, and cardiovascular benefit comparable to pharmaceutical agents. It is increasingly described as having “metformin-like” AMPK-activating properties. See sourcing options below.
Evidence for Berberine Applications
Blood glucose and type 2 diabetes: Multiple human RCTs demonstrate berberine (500 mg three times daily) reduces fasting blood glucose, HbA1c, and post-prandial glucose with efficacy comparable to metformin in direct head-to-head trials. AMPK activation (reducing hepatic glucose output), alpha-glucosidase inhibition (slowing carbohydrate absorption), and GLP-1 secretion enhancement are the primary documented mechanisms. A large meta-analysis confirmed consistent glycaemic reduction across independent trials. Claim strength: High.
Lipid metabolism: Human RCTs show berberine reduces total cholesterol (14–20%), LDL-C (11–25%), and triglycerides (17–35%) while modestly increasing HDL-C. Mechanism: PCSK9 inhibition (the same target as expensive pharmaceutical PCSK9 inhibitor monoclonal antibodies) alongside LDL receptor upregulation via LDLR gene expression. This is a pharmacologically differentiated mechanism among natural compounds. Claim strength: High.
Gut microbiome modulation: Berberine selectively promotes beneficial gut bacteria (Akkermansia muciniphila, Lactobacillus, Bifidobacterium) and inhibits dysbiotic species. Gut microbiome modulation is now recognised as a primary mechanism through which berberine exerts its metabolic effects, particularly in individuals with dysbiosis-associated insulin resistance. Claim strength: Moderate.
Dosage & Formulator Specification
Clinical dose: 500 mg berberine HCl three times daily (1500 mg/day total) with meals — the dose used in the majority of RCTs showing glycaemic and lipid benefits. Twice-daily dosing (750 mg twice daily) is also used. Lower doses (300–500 mg/day) are used for gut health and preventive applications. Take with meals to improve absorption and reduce GI side effects.
Berberine HCl (hydrochloride salt) is the most commercially available and bioavailability-referenced form. Berberine base has lower solubility; HCl salt is preferred. For enhanced bioavailability: berberine-phytosome (phospholipid complex) improves absorption 3–5-fold in animal studies; dihydroberberine (DHB) is absorbed up to 5-fold better than berberine and reconverted to berberine in tissues. DHB is an emerging commercial format but not yet widely available.
GI side effects (nausea, constipation, diarrhoea) at therapeutic doses affect approximately 10–20% of users in RCTs and are the primary compliance barrier. Starting at lower doses and titrating up, and always dosing with food, significantly reduces GI adverse effects. Include this dosing guidance in formulation documentation.
Frequently Asked Questions — Berberine
Is berberine a natural alternative to metformin?
Berberine shares AMPK activation (metformin’s primary mechanism) and has demonstrated comparable glycaemic control to metformin in direct RCT comparisons. However, it cannot be positioned as a drug substitute — pharmaceutical comparisons require drug regulatory pathways. Berberine is positioned as a dietary supplement with mechanistic overlap with AMPK-activating drugs. For individuals seeking dietary support for healthy blood glucose already in the normal range, berberine has the strongest evidence base of any widely available botanical supplement for this application.
Does berberine inhibit CYP450 enzymes and cause drug interactions?
Yes — berberine is a CYP3A4 and CYP2D6 inhibitor, with documented drug interactions with cyclosporine, digoxin, and some anticoagulants. This is clinically important given that many individuals taking berberine for metabolic syndrome may also be on pharmaceutical medications for the same conditions. Standard advisory language recommending consultation with a healthcare provider before combining berberine with prescription medications is mandatory.
Can berberine be taken alongside metformin?
Berberine and metformin share AMPK activation pathways, suggesting potential additive or synergistic glycaemic effects. Small human studies have examined combined use with positive results, but also raised considerations around hypoglycaemia risk in combined use. If both are used simultaneously, blood glucose monitoring is advisable. Medical supervision is recommended for individuals managing diagnosed diabetes.
What is the difference between berberine 95% HCl and berberine 98% from Coptis?
Chemically identical berberine hydrochloride; the difference is the purity level and botanical source declaration. The 98% grade from Coptis (Huang Lian) is the highest-purity commercial form, appropriate for premium formulations where exact dosing and botanical transparency are priorities. The 95% Berberis aristata grade delivers comparable pharmacological activity at a slightly lower purity threshold.
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery